Search Results for "action"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for action. Results 331 to 340 of 340 total matches.

Suflave — A Low-Volume Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
regimens are hyperosmotic and require consumption of 2-3 liters of fluid.1 MECHANISM OF ACTION — Suflave ...
The FDA has approved Suflave (Sebela/Braintree), a low-volume polyethylene glycol (PEG)- and sulfate-based product for cleansing of the colon prior to colonoscopy in adults. Other oral colonoscopy preparations available in the US are listed in Table 2. Suflave is marketed as tasting better than other products.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):148-51   doi:10.58347/tml.2023.1685b |  Show IntroductionHide Introduction

Opioids for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
of action than many opioid analgesics, and it could precipitate a dangerously prolonged period ...
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Med Lett Drugs Ther. 2022 Dec 12;64(1665):193-200 |  Show IntroductionHide Introduction

Drugs for Anxiety Disorders

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023  (Issue 1682)
rapid onset of action. Both drugs can cause respiratory depression and may be abused. Buspirone is FDA ...
Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8   doi:10.58347/tml.2023.1682a |  Show IntroductionHide Introduction

Drugs for Hypothyroidism

   
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023  (Issue 1670)
absorbed (95- 100% vs 70-80% absorption of LT4), has an onset of action of about 2-4 hours ...
Primary hypothyroidism is usually the result of Hashimoto's (autoimmune) thyroiditis, thyroidectomy, or radioactive iodine therapy. Treatment of hypothyroidism with replacement doses of thyroid hormone is usually lifelong. Levothyroxine (LT4; synthetic thyroxine; Synthroid, and others) is the drug of choice.1
Med Lett Drugs Ther. 2023 Feb 20;65(1670):25-9   doi:10.58347/tml.2023.1670a |  Show IntroductionHide Introduction

Drugs for Asthma

   
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024  (Issue 1716)
of acute bronchoconstriction. SABAs have a more rapid onset of action. Adverse Effects – Ipratropium can ...
The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations in the emergency department is not discussed here.
Med Lett Drugs Ther. 2024 Nov 25;66(1716):185-92   doi:10.58347/tml.2024.1716a |  Show IntroductionHide Introduction

Drugs for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023  (Issue 1672)
and the duration of action is ~3-12 months. Urinary retention and urinary tract infection are common ...
In overactive bladder, involuntary bladder contractions due to detrusor overactivity result in urinary urgency, frequency, nocturia, and incontinence. The prevalence of the disorder increases with age. Nonpharmacologic treatment, including bladder training, urge suppression, pelvic floor muscle exercises, constipation management, modification of fluid intake, and avoidance of dietary irritants such as alcohol and caffeine, should be tried first.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):41-5   doi:10.58347/tml.2023.1672a |  Show IntroductionHide Introduction

Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
; 184:450. MECHANISMS OF ACTION — Tralokinumab – IL-13 is thought to play a key role ...
The subcutaneously injected interleukin-13 (IL-13) antagonist tralokinumab-ldrm (Adbry – Leo) and the oral Janus kinase (JAK) inhibitors abrocitinib (Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie) have been approved by the FDA for treatment of moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5   doi:10.58347/tml.2023.1673b |  Show IntroductionHide Introduction

Drugs for Dementia

   
The Medical Letter on Drugs and Therapeutics • Mar 30, 2026  (Issue 1751)
, and generics) is FDA-approved for treatment of moderate to severe AD dementia. Its mechanism of action in AD ...
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline also occurs in other neurological conditions, such as Parkinson's disease, Lewy body dementia, vascular dementia, and frontotemporal dementia.
Med Lett Drugs Ther. 2026 Mar 30;68(1751):49-56   doi:10.58347/tml.2026.1751a |  Show IntroductionHide Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2023  (Issue 1676)
-Step (Foundation Consumer Healthcare) Take Action (Teva Women’s) 1. Available only by prescription ...
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective in preventing pregnancy. When used alone, barrier and behavioral methods generally have higher failure rates than other methods (see Table 1). Selection of a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80   doi:10.58347/tml.2023.1676a |  Show IntroductionHide Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 27, 2024  (Issue 1703)
, have a longer duration of action, and, in some studies, have been more effective in lowering blood pressure ...
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8   doi:10.58347/tml.2024.1703a |  Show IntroductionHide Introduction